Evidence map›Paper›PMID 35764393›Full record

Trial reportClinical journal of the American Society of Nephrology : CJASN2022

Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2- Recovered Dialysis Patients.

Philippe Attias, Imane Azzaoui, Khalil El Karoui, Andréa de La Selle, Aurélien Sokal, Pascal Chappert, Philippe Grimbert, Ignacio Fernandez, Magali Bouvier, Chloé Samson and 7 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04402892 (SARS-CoV-2 Specific Memory B and T- CD4+ Cells), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04402892 naunknown statusnot on this map

SARS-CoV-2 Specific Memory B and T- CD4+ Cells

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2020 to 2021Enrolled60ConditionsCOVID-19, SARS-CoV-2 InfectionArms35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients ), 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)
3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia · 2022
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Philippe AttiasDepartment of Nephrology and Dialysis, Hôpital Privé Nord Parisien, Sarcelles, France.
Imane AzzaouiDepartment of Internal medicine, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Creteil, France.
Khalil El KarouiAssistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Department of Nephrology, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Creteil, France.
Andréa de La SelleInstitut Necker Enfants Malades, Institut National de la Santé et de la Recherche Médical U1151/Centre National de Recherche Scientifique Unité Mixtes de Service 8253, Université de Paris, Paris, France.ORCID 0000-0002-9098-0107
Aurélien SokalDepartment of Internal medicine, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Creteil, France.
Pascal ChappertInstitut Necker Enfants Malades, Institut National de la Santé et de la Recherche Médical U1151/Centre National de Recherche Scientifique Unité Mixtes de Service 8253, Université de Paris, Paris, France.
Philippe GrimbertAssistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Department of Nephrology, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Creteil, France.
Ignacio FernandezInstitut Pasteur, Unité de Virologie Structurale, Centre National de Recherche Scientifique Unité Mixte de Recherche 3569, Paris, France.
Magali BouvierDépartement de Virologie, Bactériologie, Hygiène et Mycologie-Parasitologie, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Creteil, France.ORCID 0000-0003-1590-5980
Chloé SamsonInstitut National de la Santé et de la Recherche Médical U955, Équipe 21, Pathophysiology of glomerular diseases, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Creteil, France.
Djamal DahmaneAssistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Department of Nephrology, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Creteil, France.
Philippe RieuDepartment of Nephrology and Dialysis, Hôpital Privé Nord Parisien, Sarcelles, France.
Patrice NizardAna Laboratoires, Sarcelles, France.
Slim FouratiDépartement de Virologie, Bactériologie, Hygiène et Mycologie-Parasitologie, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Creteil, France.
Hamza SakhiAssistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Department of Nephrology, Centre de Référence Maladie Rare Syndrome Néphrotique Idiopathique, Fédération Hospitalo-Universitaire Innovative Therapy for Immune Disorders, Creteil, France.ORCID 0000-0003-4977-2661
Matthieu MahévasDepartment of Internal medicine, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Creteil, France.
Mondor NephroCov Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesAfter two doses of mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), patients on dialysis show a defective humoral response, but a third dose could increase anti-SARS-CoV-2 spike IgG titers. Responses could be different in virus-naive and SARS-CoV-2-recovered patients on dialysis. However, characterization of memory B cell response after three doses is lacking. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We evaluated the dynamics of antireceptor binding domain IgG titers and antireceptor binding domain memory B cells until 6 months after two and three doses (administered within 6 months after the second dose) of mRNA vaccine in SARS-CoV-2-recovered and virus-naive dialysis populations. Results were analyzed by ordinary one-way ANOVA, the Kruskal-Wallis test, or the Wilcoxon matched-pairs test as appropriate.

resultsIn total, 108 individuals (59 patients on dialysis and 49 controls) were included. In virus-naive patients on dialysis, antireceptor binding domain IgG response was quantitatively lower after two doses compared with healthy controls, but IgG titers increased by three-fold after three doses (

conclusionsThe third dose of mRNA vaccine given within 6 months after the second dose boosts serologic and memory response in virus-naive patients but not in SARS-CoV-2-recovered patients on dialysis. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells (MEMO-COV2), NCT04402892.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralHumansImmunityImmunoglobulin GmRNA VaccinesRenal DialysisVaccinationVaccines, SyntheticAntibodies, ViralImmunoglobulin GmRNA VaccinesVaccines, SyntheticCOVID-19dialysisimmunologymemory B cellsmRNA vaccineSARS-CoV-2

Identifiers

PMID35764393
PMCPMC9269639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.